Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice

Virology Journal

Volumn 10, Issue , 2013, Pages

  Fu, Yuan Hui ^a   He, Jin Sheng ^a   Qiao, Wei ^b   Jiao, Yue Ying ^a   Hua, Ying ^a   Zhang, Ying ^a   Peng, Xiang Lei ^a   Hong, Tao ^a,c  

^a BEIJING JIAOTONG UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Fusion glycoprotein; Helper dependent adenovirus vectors; Human respiratory syncytial virus; Immune responses; Protective immunity

Indexed keywords

ADENOVIRUS VECTOR; HELPER DEPENDENT ADENOVIRAL VECTOR FUSION VIRUS GLYCOPROTEIN VACCINE; IMMUNOGLOBULIN G; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; LUNG HOMOGENATE; MOUSE; NONHUMAN; PARAMYXOVIRUS INFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPLEEN CELL; VACCINATION;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN G; LUNG; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS; VIRAL LOAD;

ADENOVIRIDAE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUS; RICE STRIPE VIRUS;

EID: 84878635908     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-183     Document Type: Article

References (24)

1. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Graham BS, Immunol Rev 2011 239 149 166 10.1111/j.1600-065X.2010.00972.x 21198670
2. Respiratory syncytial virus in young children. Hall CB, Lancet 2010 375 1500 1502 10.1016/S0140-6736(10)60401-1 20399494
3. Respiratory syncytial virus and metapneumovirus. Collins PL, Crowe JE, Fields virology, Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, 5 2007 1601 1646
4. Respiratory syncytial virus and parainfluenza virus vaccines. Karron RA, Vaccines Philadelphia: Saunders, Elsevier, Plotkin SA, Orenstein WA, Offit P, 5 2008 1283 1293
5. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, et al. J Infect Dis 2005 191 1093 1104 10.1086/427813 15747245 (Pubitemid 40404368)
6. Respiratory syncytial virus (RSV) vaccines-two steps back for one leap forward. Power UF, J Clin Virol 2008 41 38 44 10.1016/j.jcv.2007.10.024 18340669 (Pubitemid 350298980)
7. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Fu Y, He J, Zheng X, Wu Q, Zhang M, Wang X, Wang Y, Xie C, Tang Q, Wei W, et al. Biochem Biophys Res Commun 2009 381 528 532 10.1016/j.bbrc.2009.02.075 19233131
8. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. Kohlmann R, Schwannecke S, Tippler B, Ternette N, Temchura VV, Tenbusch M, Uberla K, Grunwald T, J Virol 2009 83 12601 12610 10.1128/JVI.01036-09 19776123
9. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Kim S, Jang JE, Yu JR, Chang J, Vaccine 2010 28 3801 3808 10.1016/j.vaccine.2010.03.032 20362203
10. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al. J Virol 2007 81 4654 4663 10.1128/JVI.02696-06 17329340 (Pubitemid 46668663)
11. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, et al. J Clin Microbiol 2006 44 3781 3783 10.1128/JCM.01249-06 17021110 (Pubitemid 46768807)
12. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. Weaver EA, Nehete PN, Buchl SS, Senac JS, Palmer D, Ng P, Sastry KJ, Barry MA, PLoS One 2009 4 5059 10.1371/journal.pone. 0005059 19333387
13. Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL. Harui A, Roth MD, Kiertscher SM, Mitani K, Basak SK, Gene Ther 2004 11 1617 1626 10.1038/sj.gt.3302332 15295617 (Pubitemid 39530098)
14. Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines. Weaver EA, Nehete PN, Nehete BP, Buchl SJ, Palmer D, Montefiori DC, Ng P, Sastry KJ, Barry MA, Viruses 2009 1 920 10.3390/v1030920 20107521
15. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice. Fu YH, He JS, Zheng XX, Wang XB, Xie C, Shi CX, Zhang M, Tang Q, Wei W, Qu JG, Hong T, Biochem Biophys Res Commun 2010 391 857 861 10.1016/j.bbrc.2009.11.152 19945423
16. Research on the methods for titrating respiratory syncytial virus. Wang XB, He JS, Fu YH, Zheng XX, Fang X, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010 24 147 149 21110441
17. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer- specific mammaglobin promoter. Shi CX, Graham FL, Hitt MM, J Gene Med 2006 8 442 451 10.1002/jgm.867 16389604
18. Preparation of helper-dependent adenoviral vectors. Ng P, Parks RJ, Graham FL, Methods Mol Med 2002 69 371 388 11987790
19. System for efficient helper-dependent minimal adenovirus construction and rescue. Hillgenberg M, Schnieders F, Loser P, Strauss M, Hum Gene Ther 2001 12 643 657 10.1089/104303401300057342 11426464 (Pubitemid 32506943)
20. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus. Yuan-hui F, Jin-sheng H, Xiao-bo W, Xian-Xian Z, Qiang W, Can X, Mei Z, Wei W, Qian T, Jing-dong S, Jian-guo Q, Tao H, Biochem Biophys Res Commun 2010 395 1 87 92 10.1016/j.bbrc.2010.03.144 20350532
21. Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection. Chang J, Srikiatkhachorn A, Braciale TJ, J Immunol 2001 167 4254 4260 11591747 (Pubitemid 32954299)
22. Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the Long strain of respiratory syncytial virus. Johnstone C, de Leon P, Medina F, Melero JA, Garcia-Barreno B, Del Val M, J Gen Virol 2004 85 3229 3238 10.1099/vir.0.80219-0 15483236 (Pubitemid 39445440)
23. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG, J Virol 2011 85 366 377 10.1128/JVI.01861-10 20980510
24. Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. Roth MD, Cheng Q, Harui A, Basak SK, Mitani K, Low TA, Kiertscher SM, J Immunol 2002 169 4651 4656 12370405 (Pubitemid 35178246) China